Robert Orlowski

Robert Orlowski

UNVERIFIED PROFILE

Are you Robert Orlowski?   Register this Author

Register author
Robert Orlowski

Robert Orlowski

Publications by authors named "Robert Orlowski"

Are you Robert Orlowski?   Register this Author

100Publications

-Reads

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

J Manag Care Spec Pharm 2018 May;24(5):487

1 Department of Lymphoma/Myeloma, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX.

View Article
May 2018

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.

Br J Cancer 2018 Feb 14;118(3):388-397. Epub 2017 Dec 14.

Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.

View Article
February 2018

C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis.

Sci Signal 2017 Dec 12;10(509). Epub 2017 Dec 12.

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article
December 2017

The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.

Neoplasia 2017 Oct 30;19(10):772-780. Epub 2017 Aug 30.

Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou 511436, China. Electronic address:

View Article
October 2017

Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes.

Oncotarget 2017 Sep 27;8(43):73723-73732. Epub 2017 Aug 27.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
September 2017

Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.

Oncotarget 2017 Aug 1;8(35):59476-59491. Epub 2017 Aug 1.

Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University and The Massey Cancer Center, Richmond, VA, USA.

View Article
August 2017

Proteasome inhibitors in cancer therapy.

Nat Rev Clin Oncol 2017 Jul 24;14(7):417-433. Epub 2017 Jan 24.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 429, Houston, Texas 77030-4009, USA.

View Article
July 2017

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2017 07 10;17(7):424-432. Epub 2017 May 10.

Section on Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.

View Article
July 2017

The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.

Br J Haematol 2017 04 15;177(1):13-26. Epub 2016 Dec 15.

Department of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.

View Article
April 2017

Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma.

Eur J Haematol 2017 Mar 1;98(3):263-268. Epub 2016 Dec 1.

Department of Stem Cell Transplantation and Cellular therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
March 2017

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Authors:
Kristin A Rand Chi Song Eric Dean Daniel J Serie Karen Curtin Xin Sheng Donglei Hu Carol Ann Huff Leon Bernal-Mizrachi Michael H Tomasson Sikander Ailawadhi Seema Singhal Karen Pawlish Edward S Peters Cathryn H Bock Alex Stram David J Van Den Berg Christopher K Edlund David V Conti Todd Zimmerman Amie E Hwang Scott Huntsman John Graff Ajay Nooka Yinfei Kong Silvana L Pregja Sonja I Berndt William J Blot John Carpten Graham Casey Lisa Chu W Ryan Diver Victoria L Stevens Michael R Lieber Phyllis J Goodman Anselm J M Hennis Ann W Hsing Jayesh Mehta Rick A Kittles Suzanne Kolb Eric A Klein Cristina Leske Adam B Murphy Barbara Nemesure Christine Neslund-Dudas Sara S Strom Ravi Vij Benjamin A Rybicki Janet L Stanford Lisa B Signorello John S Witte Christine B Ambrosone Parveen Bhatti Esther M John Leslie Bernstein Wei Zheng Andrew F Olshan Jennifer J Hu Regina G Ziegler Sarah J Nyante Elisa V Bandera Brenda M Birmann Sue A Ingles Michael F Press Djordje Atanackovic Martha J Glenn Lisa A Cannon-Albright Brandt Jones Guido Tricot Thomas G Martin Shaji K Kumar Jeffrey L Wolf Sandra L Deming Halverson Nathaniel Rothman Angela R Brooks-Wilson S Vincent Rajkumar Laurence N Kolonel Stephen J Chanock Susan L Slager Richard K Severson Nalini Janakiraman Howard R Terebelo Elizabeth E Brown Anneclaire J De Roos Ann F Mohrbacher Graham A Colditz Graham G Giles John J Spinelli Brian C Chiu Nikhil C Munshi Kenneth C Anderson Joan Levy Jeffrey A Zonder Robert Z Orlowski Sagar Lonial Nicola J Camp Celine M Vachon Elad Ziv Daniel O Stram Dennis J Hazelett Christopher A Haiman Wendy Cozen

Cancer Epidemiol Biomarkers Prev 2016 12 1;25(12):1609-1618. Epub 2016 Sep 1.

Keck School of Medicine of USC and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.

View Article
December 2016

Integration of Novel Agents into the Care of Patients with Multiple Myeloma.

Clin Cancer Res 2016 Nov 14;22(22):5443-5452. Epub 2016 Nov 14.

Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.

View Article
November 2016

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Eur J Haematol 2016 Oct 15;97(4):342-7. Epub 2016 Feb 15.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article
October 2016

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Clin Cancer Res 2016 Oct 13;22(19):4901-4912. Epub 2016 Jun 13.

Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
October 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article
October 2016

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol 2016 05 14;34(13):1544-57. Epub 2016 Mar 14.

Meletios A. Dimopoulos, Efstathios Kastritis, and Evangelos Terpos, National and Kapodistrian University of Athens, Athens, Greece; Pieter Sonneveld, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands; Nelson Leung and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center, Houston, TX; David H. Vesole, Hackensack University Medical Center, Hackensack, NJ; Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Brian G.M. Durie, Samuel Oschin Cancer Center, Los Angeles, CA; Giampaolo Merlini, Scientific Institute Policlinico San Matteo and University of Pavia, Pavia; Antonio Palumbo, University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino; Michele Cavo, Bologna University School of Medicine, S.Orsola's University Hospital, Bologna, Italy; Heinz Ludwig, Wilhelminenspital, Vienna, Austria; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg; Hermann Einsele, Wuerzburg University Medical Center, Wuerzburg, Germany; Douglas Joshua, Royal Prince Alfred Hospital, Sydney University Medical School, Sydney, New South Wales, Australia; Raymond Powles, Cancer Centre London, London, United Kingdom; Laurent Garderet, Saint Antoine Hospital & University of "Pierre et Marie Curie" Paris-6, Paris; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France; and Jesús San Miguel, Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article
May 2016

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma.

J Biol Chem 2015 Dec 19;290(50):29854-68. Epub 2015 Oct 19.

the Departments of Lymphoma and Myeloma and Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030

View Article
December 2015

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.

Clin Lymphoma Myeloma Leuk 2015 Nov 5;15(11):687-93. Epub 2015 Aug 5.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address:

View Article
November 2015

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy.

Blood 2015 Nov 14;126(22):2475-8. Epub 2015 Oct 14.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR.

View Article
November 2015

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Oncotarget 2015 Oct;6(33):34329-41

Department of Lymphoma and Myeloma, Division of Cancer Medicine, Center for Cancer Immunology Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
October 2015

Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.

Nat Commun 2015 Oct 12;6:8428. Epub 2015 Oct 12.

The Vontz Center for Molecular Studies, Department of Cancer and Cell Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267, USA.

View Article
October 2015

Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.

Ann Hematol 2015 Sep 5;94(9):1605-7. Epub 2015 Jun 5.

Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA,

View Article
September 2015

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

J Clin Oncol 2015 Sep 3;33(26):2863-9. Epub 2015 Aug 3.

Antonio Palumbo, Stefania Oliva, Simona Caltagirone, Sara Bringhen, and Francesca Gay, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute della Salute e della Scienza di Torino; Roberto Passera, University of Torino, Torino; Massimo Offidani, Clinica di Ematologia, AUO Ospedali Riuniti di Ancona, Ancona; Pellegrino Musto, Istituto di Ricovero e Cura a Carattere Scientifico, Referral Cancer Center of Basilicata, Rionero in Vulture; Maria T. Petrucci, Sapienza University of Rome, Rome; Elena Zamagni and Michele Cavo, Istituto di Ematologia Seragnoli, Università di Bologna, Bologna, Italy; Hervé Avet-Loiseau and Michel Attal, Institut Claudius Regaud, L'Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse; Thierry Facon, Service des Maladies du Sang, Hôpital Claude Huriez, Centre Hospitalier Regionale et Universitaire Lille, Lille; Philippe Moreau, University Hospital Hotel-Dieu, Nantes, France; Henk M. Lokhorst, VU University Medical Center, Amsterdam; Pieter Sonneveld, Erasmus MC, Rotterdam, the Netherlands; Hartmut Goldschmidt, University Hospital and National Center for Tumor Diseases Heidelberg, Heidelberg, Germany; Laura Rosinol, Hospital Clínic, Institut Clínic d'Investigacions Biomèdiques Ausgust Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jésus San Miguel, Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas, IDISNA, Pamplona, Spain; Paul Richardson and Kenneth C. Anderson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA; Shaji Kumar and S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Sagar Lonial, Winship Cancer Institute, Emory University, Atlanta, GA; Robert Z. Orlowski, The University of Texas MD Anderson Comprehensive Cancer Center, Houston, TX; Gareth Morgan, Myeloma Institutes for Research Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; Brian G.M. Durie, Cedars-Sinai Comprehensive Canc

View Article
September 2015

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

N Engl J Med 2015 Aug 2;373(7):621-31. Epub 2015 Jun 2.

From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).

View Article
August 2015

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Clin Cancer Res 2015 Jun 6;21(11):2538-45. Epub 2015 Mar 6.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article
June 2015

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.

PLoS One 2014 2;9(9):e103015. Epub 2014 Sep 2.

Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.

View Article
May 2015

Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.

Oncotarget 2015 Apr;6(11):8567-78

Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
April 2015

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Int J Cancer 2015 Mar 23;136(5):991-1002. Epub 2014 Jul 23.

Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.

View Article
March 2015

Approach to patients with primary refractory acute myeloid leukemia.

Curr Opin Hematol 2015 Mar;22(2):97-107

Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article
March 2015

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.

Leuk Res 2015 Mar 3;39(3):371-9. Epub 2015 Jan 3.

Department of Pediatrics Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0853, Houston, TX 77030, USA; The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, 6767 Bertner Avenue, Houston, TX 77030, USA. Electronic address:

View Article
March 2015

Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.

Neoplasia 2015 Mar;17(3):289-300

Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

View Article
March 2015

Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics.

Cancer Inform 2014 7;13(Suppl 2):113-23. Epub 2014 Dec 7.

Associate Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article
December 2014

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Blood 2014 Oct 10;124(17):2687-97. Epub 2014 Sep 10.

Division of Hematology/Oncology, Department of Medicine, Virginia Commonwealth University and the Massey Cancer Center, Richmond, VA; Virginia Institute of Molecular Medicine, Virginia Commonwealth University, Richmond VA.

View Article
October 2014

Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.

Mol Cell Biol 2014 Sep 7;34(18):3435-49. Epub 2014 Jul 7.

Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia, USA Department of Biochemistry, Virginia Commonwealth University and Massey Cancer Center and Virginia Institute of Molecular Medicine, Richmond, Virginia, USA

View Article
September 2014